Sökning: "urinary bladder carcinoma"
Visar resultat 1 - 5 av 27 avhandlingar innehållade orden urinary bladder carcinoma.
1. Quantitative immunochemistry in tissue sections : With special reference to urinary bladder carcinoma
Sammanfattning : Urinary bladder carcinoma affects about 2 000 people in Sweden every year. It is a heterogeneous disease and for adequate treatment decisions, prognostic tools are needed. Many of these are based on immunohistochemistry (MC) and hampered by poorly reproducible methodologies and subjective evaluations. LÄS MER
2. Stage T1 Urinary Bladder Carcinoma : Investigation of A Population-Based Cohort
Sammanfattning : Approximately 2 300 new cases of urinary bladder carcinoma (UBC) are diagnosed every year in Sweden. This type of cancer is characterized as a long-standing disease with a high risk of recurrence and progression from an indolent to a more aggressive course. LÄS MER
3. Cancer Immunotherapy : A Preclinical Study of Urinary Bladder Cancer
Sammanfattning : Bacillus Calmette Guérin (BCG), or attenuated Mycobacterium bovis, is the gold standard of immunotherapy in the clinic to treat superficial bladder cancer. However, setbacks remain due to a high recurrence rate, side effects, and BCG-refractory disease. LÄS MER
4. Urinary bladder carcinoma, preclinical and clinical studies on EGFR based targeting
Sammanfattning : Radical cystectomy with bilateral pelvic lymphadenectomy is the standard treatment for muscle-invasive transitional cell carcinoma of the urinary bladder. Despite presumably localised malignancies and efficacious management about 50% of patients will die within 5 years, the majority due to metastatic disease. LÄS MER
5. Urinary Bladder Carcinoma – Studies of Outcome of Current Management and Experimental Therapy
Sammanfattning : The thesis concerns the epidemiology, current and possible future treatment of urothelial cancer of the urinary bladder. The Swedish National Quality Registry for Bladder Cancer 1997-2001 was used to explore epidemiology, current therapies and outcome. More common in men, the incidence for Ta and T1 tumours peaks in the age range 70-79 years. LÄS MER